Actelion declines Trophos option as olesoxime crashes in Phase III
This article was originally published in Scrip
Trophos' lead compound, olesoxime, has failed a Phase III study in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). As a result, Actelion will not be exercising its option to acquire Trophos under a €10 million acquisition option agreement signed last year (scripintelligence.com, 20 July 2010).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.